Beam Therapeutics (BEAM) EBITDA (2019 - 2026)

Beam Therapeutics (BEAM) has reported EBITDA for 8 consecutive years, with -$107.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 10.12% year-over-year to -$107.2 million; the TTM figure through Mar 2026 stood at -$371.6 million (up 13.72% YoY), while the FY2025 annual figure was -$383.7 million, up 7.67% from the prior year.
• EBITDA eased to -$107.2 million in Q1 2026 per BEAM's latest filing, from -$17.4 million in the prior quarter.
• Across five years, EBITDA topped out at $132.9 million in Q4 2023 and bottomed at -$126.8 million in Q3 2025.
• Historically, EBITDA has averaged -$83.6 million across 5 years, with a median of -$102.1 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA jumped 249.3% — and 2024, when it tumbled 175.3%.
• Beam Therapeutics' EBITDA stood at -$89.0 million in 2022, then surged by 249.3% to $132.9 million in 2023, then sank by 175.3% to -$100.0 million in 2024, then soared by 82.56% to -$17.4 million in 2025, then slumped by 514.59% to -$107.2 million in 2026.
• Business Quant data shows BEAM's EBITDA at -$107.2 million in Q1 2026, -$17.4 million in Q4 2025, and -$126.8 million in Q3 2025.